Clinical Colorectal Cancer

Clinical Colorectal Cancer - ISSN 1533-0028
Source Normalized Impact per Paper (SNIP): 1.17 Source Normalized Impact per Paper (SNIP):
SNIP measures contextual citation impact by weighting citations based on the total number of citations in a subject field.
SCImago Journal Rank (SJR): 1.402 SCImago Journal Rank (SJR):
SJR is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and a qualitative measure of the journal’s impact.
Impact Factor: 4.481 (2020) Impact Factor:
The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
5 Year Impact Factor: 4.538 (2020) Five-Year Impact Factor:
To calculate the five year Impact Factor, citations are counted in 2016 to the previous five years and divided by the source items published in the previous five years.
© 2017 Journal Citation Reports ® (Clarivate Analytics, 2017)
Volumes: Volume 1
Issues: 4 issues
ISSN: 15330028
Editor-in-Chief: Chu

Personal Subscription

Sales tax will be calculated at check-out Price includes VAT/GST

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.


Clinical Colorectal Cancer is devoted to manuscripts that focus on early detection/screening, diagnosis, prevention, and treatment of colorectal cancer and other GI cancers, including pancreatic, liver, gastric/gastroesophageal, biliary, and other gastrointestinal cancers. The major emphasis is on recent scientific developments and original peer-reviewed manuscripts. Specific areas of interest include original reports on clinical research and/or translational research and translational correlative science that is directly related to clinical trials, in all (multidisciplinary) therapeutic fields that relate to colorectal cancer and other GI cancers.

Further areas of interest include original research on drug sensitivity and resistance to cytotoxic agents, targeted therapies, immunotherapies, and other novel therapeutic approaches; pathology, (validated) predictive markers, and prognostic indicators; chemoprevention strategies; and integration of various therapeutic and multidisciplinary approaches. A much lower priority will be given to meta-analyses, pooled analyses, and real-world analyses unless the knowledge gained from such reports is significant and can be applied to clinical practice. In addition, unsolicited reviews are not encouraged unless there has been a discussion with the editor or deputy editors as the journal wants to ensure that reviews will provide real added value and true gain of knowledge.